The Company is a Korea-based company mainly engaged in the production and sale of immunotherapy products. Major products include anticancer T cell therapies and antibody therapies. The Company was established on February 27, 2015. The Company share was listed on the Korea Securities Dealers Automated Quotation System ( KOSDAQ ) on December 24, 2018.
Headquarters
1401, 25, Gasan Digital 1-Ro, Geumcheon-Gu
Seoul; Seoul;
Contact Details: Purchase the Eutilex Co.,Ltd. report to view the information.
Website: http://www.eutilex.com
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service